PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26796063-0	2016	Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.	CUDC-907	67-75	ATP binding cassette subfamily A member 4	Homo sapiens	6-38	
26796063-0	2016	Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.	CUDC-907	67-75	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	39-44	
26796063-0	2016	Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.	CUDC-907	67-75	histone deacetylase 9	Homo sapiens	97-116	
26796063-0	2016	Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.	CUDC-907	67-75	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	121-150	
26796063-1	2016	CUDC-907 is a novel, dual-acting small molecule compound designed to simultaneously inhibit the activity of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).	CUDC-907	0-8	histone deacetylase 9	Homo sapiens	108-127	
26796063-1	2016	CUDC-907 is a novel, dual-acting small molecule compound designed to simultaneously inhibit the activity of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).	CUDC-907	0-8	histone deacetylase 9	Homo sapiens	129-133	
26796063-1	2016	CUDC-907 is a novel, dual-acting small molecule compound designed to simultaneously inhibit the activity of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).	CUDC-907	0-8	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	139-168	
26796063-2	2016	Treatment with CUDC-907 led to sustained inhibition of HDAC and PI3K activity, inhibition of RAF-MEK-MAPK signaling pathway, and inhibition of cancer cell growth.	CUDC-907	15-23	histone deacetylase 9	Homo sapiens	55-59	
26796063-2	2016	Treatment with CUDC-907 led to sustained inhibition of HDAC and PI3K activity, inhibition of RAF-MEK-MAPK signaling pathway, and inhibition of cancer cell growth.	CUDC-907	15-23	zinc fingers and homeoboxes 2	Homo sapiens	93-96	
26796063-2	2016	Treatment with CUDC-907 led to sustained inhibition of HDAC and PI3K activity, inhibition of RAF-MEK-MAPK signaling pathway, and inhibition of cancer cell growth.	CUDC-907	15-23	mitogen-activated protein kinase kinase 7	Homo sapiens	97-100	
26796063-6	2016	In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells.	CUDC-907	78-86	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	30-35	
26796063-6	2016	In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells.	CUDC-907	78-86	histone deacetylase 9	Homo sapiens	190-194	
26796063-6	2016	In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells.	CUDC-907	125-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	30-35	
26796063-6	2016	In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells.	CUDC-907	125-133	histone deacetylase 9	Homo sapiens	190-194	
26796063-6	2016	In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells.	CUDC-907	125-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	30-35	
26796063-6	2016	In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells.	CUDC-907	125-133	histone deacetylase 9	Homo sapiens	190-194	
26796063-7	2016	Moreover, although CUDC-907 affects the transport function of ABCG2, it was not potent enough to reverse drug resistance mediated by ABCG2 or affect the expression level of ABCG2 in human cancer cells.	CUDC-907	19-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	62-67	
26796063-8	2016	Taken together, our findings indicate that ABCG2-mediated CUDC-907 resistance can have serious clinical implications and should be further investigated.	CUDC-907	58-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	43-48	
26796063-9	2016	More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials.	CUDC-907	54-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	66-71	
26796063-9	2016	More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials.	CUDC-907	54-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	146-151	
26796063-9	2016	More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials.	CUDC-907	54-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	146-151	
26796063-9	2016	More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials.	CUDC-907	207-215	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	66-71	
26796063-9	2016	More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials.	CUDC-907	207-215	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	146-151	
26796063-9	2016	More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials.	CUDC-907	207-215	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	146-151	
26796063-9	2016	More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials.	CUDC-907	207-215	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	66-71	
26796063-9	2016	More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials.	CUDC-907	207-215	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	146-151	
26796063-9	2016	More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials.	CUDC-907	207-215	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	146-151